Among the biopsied patients with CTC data, this paucity of p16 response in the V+ CTC population was consistent with the lack of qualitative tumor p16 modulation as detected by IHC at C1W3, suggesting that changes (or lack thereof) in p16 protein expression in V+ CTCs may reflect those in tumor tissue. The gene discussed is CDKN2A; the disease is neoplasm.